Drug Trial Radar · NCT00444665
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
Last checked: Nov 19, 2026Latest source record: Nov 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
750
Planned (sponsor's estimate)
Start
May 2007
Primary completion
Aug 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Mar 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.
Conditions
- Glaucoma
Interventions
Travatan-ZDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Surface Disease Symptoms
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fridley
Fridley, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.